## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Mifepristone (Korlym)

## Notes:

 ^ Trans-sphenoidal surgery for pituitary dependent Cushing's or surgical removal of an adrenocortical tumor or a source of ectopic ACTH in malignant Cushing's.

<u>Initiation (new start) criteria</u>: Non-formulary mifepristone (Korlym) will be covered for <u>12 months</u> on the prescription drug benefit when the following criteria are met:

- Patient is at least 18 years of age
- Diagnosis of endogenous Cushing's syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)
- Diagnosis of type 2 diabetes mellitus -OR- patient has glucose intolerance (defined as a 2-hour glucose tolerance test glucose value of 140-199 mg/dL)
- Patient has failed surgical resection<sup>^</sup> -OR- patient is not a candidate for surgical resection<sup>^</sup>
- All of the following if patient is a female of reproductive potential:
  - Baseline (within previous month) negative pregnancy test prior to start of therapy.
  - Must agree to use a non-hormonal medically acceptable method of contraception during and for one month after mifepristone therapy.
  - o No history of unexplained vaginal bleeding.
  - Must not have endometrial hyperplasia with atypia or endometrial carcinoma.

<u>Continued use criteria (12 months after initiation)</u>: Non-formulary <u>mifepristone</u> (**Korlym**) will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Documentation of <u>at least one</u> of the following:
  - o Patient has improved glucose tolerance while on mifepristone therapy
  - Patient has stable glucose tolerance while on mifepristone therapy

kp.org

Revised: 08/09/18 Effective: 09/20/18 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

